Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Anlotinib in Advanced Pulmonary Pleomorphic Carcinoma
NCT05375734Phase 2Completed
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Aug 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma (PSC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2021; status: completed.
02
Drugs
tislelizumabanlotinib
03
Conditions
pulmonary sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on NCT05375734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375734.